Alpha Tau Medical Ltd. (DRTSW)
| Market Cap | 1.11B +400.9% |
| Revenue (ttm) | n/a |
| Net Income | -92.57M |
| EPS | -1.05 |
| Shares Out | 92.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 95,521 |
| Open | 1.780 |
| Previous Close | 1.920 |
| Day's Range | 1.700 - 1.850 |
| 52-Week Range | 0.280 - 4.620 |
| Beta | 1.29 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 1, 2026 |
About DRTSW
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the trea... [Read more]
News
Alpha Tau Medical Transcript: Study update
REGAIN interim data showed 100% feasibility, five complete and one partial response among six assessed patients, and no local recurrence; all eight treated patients were alive at median follow-up of ~7 months. Enrollment is expanding to 20, with a further interim update targeted for Q1 2027.
Alpha Tau announces updated interim results from REGAIN trial of Alpha DaRT
Alpha Tau (DRTS) Medical announced updated interim results from its U.S. REGAIN trial of Alpha DaRT for patients with recurrent glioblastoma, GBM. The results, measured as of November 11, 2026,ā¦
Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRTĀ® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16
- All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment (...
Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRTĀ® Recurrent Glioblastoma REGAIN Trial
JERUSALEM, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq/TASE: DRTS, DRTSW) (āAlpha Tauā), the developer of the innovative alpha-radiation cancer therapy Alpha DaRTĀ®, today announce...
Alpha Tau upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler upgraded Alpha Tau (DRTS) to Overweight from Neutral with a $22 price target The firm view Alpha DaRT as a differentiated technology with potential across multiple solid tumors,ā¦
Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange
Funds that track these TASE benchmark indexes are expected to add Alpha Tau shares to their holdings TA-125 tracks the 125 largest and most prominent companies on the TASE JERUSALEM, Oct. 29, 2026 (GL...
Alpha Tau signs MOU with Samsung Medical Center in Seoul
Alpha Tau (DRTS) announced the signing of an MOU in Seoul, South Korea, with Samsung Medical Center, or SMC, regarding a potential clinical trial in pancreatic cancer patients. Any suchā¦
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRTĀ® for Pancreatic Cancer Patients in Korea
- MOU relates to a potential clinical trial in South Korea, Alpha DaRT's first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology - - In Korea, on...
Alpha Tau Medical Slides: Investor presentation
Alpha Tau Medical has posted slides in relation to its latest quarterly earnings report, which was published on October 22, 2026.
Alpha Tau announces FDA approval of REGAIN trial IDE supplement
Alpha Tau (DRTS) announced that the FDA has approved an investigational device exemption, or IDE, supplement expanding its U.S. REGAIN trial. The company also announced that an abstract has beenā¦
Alpha Tau Announces FDA Approval to Expand Alpha DaRTĀ® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
- FDA approves IDE supplement expanding REGAIN from 10 to 20 patients, with additional study endpoints and interim analysis - - Abstract authored by REGAIN study principal investigator Dr. Joshua Palm...
Alpha Tau to Participate in October Investor Conferences
JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the āCompanyā) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRTĀ®, t...
Alpha Tau price target raised to $30 from $17 at Barclays
Barclays raised the firmās price target on Alpha Tau (DRTS) to $30 from $17 and keeps an Overweight rating on the shares. The firm has a bullish stance on theā¦
Alpha Tau to Participate in September Investor Conferences
JERUSALEM, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd.
Alpha Tau completes patient enrollment in IMPACT study
Alpha Tau (DRTS) announced the completion of patient enrollment in its IMPACT study ā a multicenter pilot study evaluating intratumoral Alpha DaRT in combination with first-line chemotherapy for patie...
Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRTĀ® Following Strong Demand and Multiple Expansions
- IMPACT, a multicenter pilot study of Alpha DaRT Ā® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12 ...
Alpha Tau price target raised to $16 from $15 at H.C. Wainwright
H.C. Wainwright raised the firmās price target on Alpha Tau (DRTS) to $16 from $15 and keeps a Buy rating on the shares post the Q2 report. The U.S. pivotalā¦
Alpha Tau reports Q2 EPS (25c), consensus (14c)
āThe second quarter of 2026 was without question the busiest and most consequential period in Alpha Tauās (DRTS) history, and the momentum has only continued to accelerate since,ā said Alphaā¦
Alpha Tau Medical Earnings release: Q2 2026
Alpha Tau Medical released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (āAlpha Tauā or the āCompanyā), the developer of the innovative alpha-radiation cancer therapy Alpha DaRTĀ®, to...
Alpha Tau reports Alpha DaRT combination study results
Alpha Tau (DRTS) announced results from a clinical study evaluating Alpha DaRT in combination with pembrolizumab in elderly patients with locally advanced and metastatic head and neck squamous cell ca...
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRTĀ® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRTĀ® in combination with pembrolizumab...
Alpha Tau treats first patient in ADMIRE study for recurrent skin cancer
Alpha Tau (DRTS) Medical announced the successful treatment of the first patient in its ADMIRE study, a clinical trial evaluating intratumoral Alpha DaRT for immunocompromised patients with recurrent ...
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson
Alpha Tau treats first glioblastoma patient in Israel with Alpha DaRT
Alpha Tau (DRTS) announced the treatment with Alpha DaRT of the first glioblastoma patient in Israel, and the first ever outside of the United States, performed at Hadassah University Medicalā¦